OptiBiotix Health PLC Manufacturing, supply & profit sharing agreement (1441V)
November 01 2017 - 3:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1441V
OptiBiotix Health PLC
01 November 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Manufacturing, supply and profit sharing agreement with Knighton
Foods
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces it has entered into a manufacturing and
supply agreement with Knighton Foods, ("Knighton"). The agreement
grants Knighton an exclusive licence to manufacture and supply
OptiBiotix's SlimBiome(R) weight management technology in the
United Kingdom, in return for 50% of the profit, with an agreed
cost of manufacture and minimum sales price per kilogramme.
Knighton, a wholly owned subsidiary of Premier Foods plc, is a
leading producer of a wide range of high quality, value adding,
functional powdered foods, specialist ingredients and finished
products, to some of the countries major supermarkets, high street
coffee houses, and best-known household brands. Knighton's advanced
powder technology was key to developing an improved version of
SlimBiome(R), providing enhanced solubility and better product
presentation, greatly improving flavour and mouthfeel.
SlimBiome(R), a patented combination of natural ingredients
developed by experts to provide hunger free weight loss, will be
supplied by Knighton as a specialised functional ingredient, into a
wide range of finished products for use in the retail, vending, and
ingredients sectors. Knighton will use their best endeavours to
promote and expand the supply of SlimBiome(R), bringing it to the
attention of product innovation teams across their wide range of
customers.
This agreement, with one of the UK's leading specialist
ingredients suppliers, is an important step in optimising the
supply chain by leveraging Knighton's purchasing power,
manufacturing efficiencies and partner network to scale up the
manufacture and supply of SlimBiome(R). This is an important step
to meet the needs of major UK retailers and exports of
SlimBiome(R), and SlimBiome(R) containing products to Tata, and
potential new partners, in the Iarge consumer markets of India and
the USA.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce the signing of a manufacturing, supply and profit sharing
agreement with Knighton Foods. We chose Knighton due to their world
leading expertise in adding value and differentiation to speciality
powdered ingredients like SlimBiome(R). Their development work
greatly improved SlimBiome's solubility, taste and mouthfeel whilst
reducing the overall cost of manufacture. We believe working with
Knighton, and similar partners around the world, provides the best
opportunity of meeting the requirements of major retailers and the
growing interest we are seeing in SlimBiome(R) from partners
worldwide."
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0883
Liam Murray
FinnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate
Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
About Knighton Foods www.knightonfoods.com
Knighton Foods, based in the U.K are a leading producer of high
quality specialist powdered products. Their suite of processes
includes, processing, blending and packaging capabilities ranging
from portion controlled sachets to 1 ton bulk containers.
Knighton's technical and R&D capabilities have been
developed over 100+ years' and deliver value and functionality to
ingredients and finished products, for use in the Retail, Out of
Home, and Ingredients sectors. Examples of which can be found on
the shelves of the UK's leading supermarkets in some of the most
recognised consumer brands, and leading chains of fast food
restaurants and coffee shops.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREFLFXDBFBFBX
(END) Dow Jones Newswires
November 01, 2017 03:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024